Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medicamen OrganicsNSE:MEDIORG +4.80%21 Gross Margin % is -56.52% as of Mar. 2026. GuruFocus rates NSE:MEDIORG with a GF Score™ of 21/100. The stock has 11 warning signs investors should review. Among 941 Drug Manufacturers companies, Medicamen Organics ranks worse than 98.94% on this metric.
Medicamen Organics Ltd gross margin has been in long-term decline. The average rate of decline per year is -1.3%.
The historical rank and industry rank for Medicamen Organics's Gross Margin % or its related term are showing as below:
NSE:MEDIORG'
s Gross Margin % Range Over the Past 10 Years
Min: -56.52 Med: 27.01 Max: 37.58
Current: -56.52
During the past 6 years, the highestGross Margin % of Medicamen Organics was 37.58%. The lowest was -56.52%. And the median was 27.01%.
NSE:MEDIORG's Gross Margin % is ranked worse than 98.94% of 941
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs NSE:MEDIORG: -56.52
Medicamen Organics had a gross margin of -56.52% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Medicamen Organics was -1.30% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Medicamen Organics had a gross margin of -56.52% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Medicamen Organics Gross Margin % Related Terms
Medicamen Organics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Medicamen Organics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MEDIORG vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Medicamen Organics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicamen Organics Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicamen Organics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Medicamen Organics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Medicamen Organics (NSE:MEDIORG) has a Gross Margin % of -56.52% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Medicamen Organics and its competitors. According to the industry distribution chart, Medicamen Organics ranks #931 out of 941 companies in the Drug Manufacturers industry, placing it in the top 98.9%.
Is Medicamen Organics' Gross Margin % too high?
Medicamen Organics' current Gross Margin % is -56.52%. Based on the distribution chart, Medicamen Organics ranks #931 out of 941 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medicamen Organics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Medicamen Organics' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medicamen Organics ranks #931 out of 941 companies for Gross Margin %. This places Medicamen Organics in the lower half of its industry. The industry median Gross Margin % is 48.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Medicamen Organics and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicamen Organics's current Gross Margin % is -56.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicamen Organics stock overvalued right now?
Medicamen Organics (NSE:MEDIORG) has a current Gross Margin % of -56.52%. The current Gross Margin % is -56.52%. Medicamen Organics' overall GF Score™ is 21/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Medicamen Organics (NSE:MEDIORG), the current Gross Margin % is -56.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medicamen Organics Ltd develops, manufactures, and distributes a wide range of pharmaceutical dosage forms, including Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders. The company operates two WHO Good Manufacturing Practice certified facilities in India, producing products for both domestic and international clients. It provides contract manufacturing and loan license services to various pharmaceutical companies and exports to several countries across Africa, CIS, and South Asia. The principal source of revenue is through the manufacturing, export, and contract services focused on generic and branded pharmaceutical formulations.
21GF Score
Get the complete analysis for NSE:MEDIORG
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MEDIORG has been successfully added to your 
